Subscribe to the newsletterForward | Contact | www.lyonbiopole.com   March 2015
 
A LA UNE
03/27/2015 - 4 projects, accredited by Lyonbiopole, obtain public funding from the 19th Call for Projects FUI

After their accreditation by Lyonbiopole, worldwide competitiveness cluster, the new projects COLOMATRIX, COINSIDE, DOGTOMAN and ROBOT-PCR have been selected by the FUI. Since 2005, Lyonbiopole has accredited 169 multi-partner R&D projects for a total R&D investment of € 777 millions of which € 312 millions have been obtained. The 4 new R&D projects, accredited by Lyonbiopole and submitted to the 19th FUI Call for Projects, benefit from public funding from the French State, local authorities among which the Rhône-Alpes Region, the Greater Lyon, General Council of Isère and FEDER European funds.
Contact : Claudia Chagneau, R&D Project Manager - claudia.chagneau@lyonbiopole.com 

Learn more


04/15-16/2015 - Investor Conference and Catalyzer have selected their projects

BIOVISION, the annual forum on future-oriented research in life sciences organized by the Fondation pour l'Université de Lyon, announces the list of biotech and medtech companies and projects selected for the Investor Conference and Catalyzer pitching sessions. The third BIOVISION Catalyzer and Investor Conference sessions continue to engage project sponsors and start-up participation from France and around the world. Between 2013 and 2015, the two sessions respectively received 180 and 200 applications.
Contact : Hugo Veysseyre, Clinical Innovation Project Manager - hugo.veysseyre@lyonbiopole.com 

Learn more



ZOOM SUR
Alizé Pharma

Alizé Pharma, a company member of Lyonbiopole,announces that it has raised €1.8 million (USD $1.94 million) in a first financing round. The funding round was supported by a syndicate of investors that included Sofimac Partners via their FCPI Emergence Innovation 1 seed capital fund, Octalfa, Sham Innovation Santé, Rhône-Alpes Création, Crédit Agricole Création, CEMA and TAB Consulting. Alizé Pharma III will use the funds to conduct a pharmacology and lead optimization program on a family of peptides with anabolic effects on the bone. The I-HBD1 program will be performed in collaboration with Alizé Pharma III’s US partner New Paradigm Therapeutics Inc., a spin-off from the University of North Carolina at Chapel Hill founded by Dr. David Clemmons. 

Learn more



A LA UNE
04/10/2015 - Facilities seminar standardization single use, Accinov

Accinov and Pharma Biot’Expert organize a seminary on standardization of single-use technology for pharmaceutical biomanufacturing. Pharma Biot’Expert is an expert consultancy company specialized in project management for pharmaceutical biomanufacturing. The company has a strong background in the implementation of single-use equipment and will present the current state-of-the-art of regulation. A comparison with medical device requirements will be made and the new standards developed by ASTM will be introduced. The seminary will be divided in two parts between presentations (1h) and case studies (1h).
Contact : Sylvain Peyrache, sylvain.peyrache@accinov.com

Learn more


05/26-27/2015 - A3P BioProduction International Congress

The association A3P organizes the 2015 Edition of the International Bioproduction Congress in Lausanne on Mai, the 26th and the 27thThe congress will be held on the Campus of the EPFL (SwissTech convention Center). The strategic stakes of pharmaceutical biomanufacturing will discuss during the presentation. Accinov will attend the congress and will facilitate a workshop on manufacturing strategies for the production of clinical batches and on early phase of biological developments.

Learn more


06/15-18/2015 - Joint the Rhône-Alpes delegation at BIO Philadelphia

Thanks to the support of the Rhône-Alpes regional council, and local administrations – Only Lyon, Grenobles Alps Metropole, and Lyon Chamber of Commerce, Lyonbiopole offers to its SMB members a tailor-made package for their participation to BIO Philadelphia 2015. Lyonbiopole's support includes financial support, broader visibility with the opportunity to be exhibitor on Lyonbiopole booth based on the French Pavilion and dedicated communication tools for the event. Visit us on the French Booth !
Contact : Simon Gudin, SMEs Development Project Manager - simon.gudin@lyonbiopole.com

Learn more


06/30-07/04/2015 - SysBioMed2015

The 10th CFGBC Symposium with ISBE and CASyM workshops will be a one day event attended by leading scientists from systems biology/medicine that are giving a joint effort inside ISBE and CASyM consortia to promote this new and exciting field in Europe and beyond. The symposium and workshops are free of admission. 

Learn more


09/23-24/2015 - Adebiotech

The association Adebiotech organizes a seminar on protein and peptide stability and formulation. Accinov, the Biomanufacturing Center of Lyonbiopole, supports the preparation of the agenda of the seminar where challenges and opportunities of protein and peptide formulation will be addressed. Attend the seminar and discover how to anticipate risks of instability, the foremost analytical methods available; how to model these phenomena and what are the latest formulation technologies to develop new biologics.

Learn more



AGENDA
Advanced Lecture Course on Computational Systems Biology
From April, 6th to 11th 2015 - Aussois ski ressort, France
The international conference "Perspectives in Environmental and Systems Biology"
From April 13th to 15th 2015 - Grenoble, France
2015 CASyM Academic Industry Interaction Workshop
April, 14th 2015 - Lyon, France
2015 Annual Meeting of the HKS Inflammation and autoimmunity
From April, 14th to 16th 2015 - Annecy, France
Biovision 2015
From April 15th to 16th, 2015 - Lyon, France
A3P BioProduction International Congress
From mai 26th to 27th, 2015 - Lausanne, Suisse
Fondation Mérieux Conférence
June 8th to 10th, 2015 - Annecy, France
International Convention BIO 2015
From June 15th to 17th 2015 - Philadelphia, US
Casym Summer School
From June 22th to 26th, 2015 - Stockholm, Swedeen
5th ICCR congress edition
From July 8th to 12th, 2015 - Quebec, Canada
Adebiotech
September 23th to 24th, 2015 - Romainville, France
 
A LA UNE
03/2015 - New call H2020 - Fast track to innovation

The European Commission launches a new initiative Fast Track to Innovation (FTI) under H2020. It aims to give to innovative companies a final push before the access to market. The projects must focus on industrial development. Consortia should bring 3-5 organizations (mostly companies). All fields of technology are concerned. Several submission dates are planned in 2015 (04/29/15 – 09/01/2015 and 12/1/2015).
Contact : Emilie Romeo, Europe Project Manager - emilie.romeo@lyonbiopole.com

Learn more


03/2015 - Eurostars : call for projects open

Eurostars call for projects is open. This funding programme is fully dedicated to innovative SMEs aiming to launch R&D projects closed to the market, that are collaborative and European (at least 2 partners from EU). The funding rate for projects goes from 30 to 40 % (subsidy managed by BPI France). The submission deadline is fixed on 09/17/2015. Lyonbiopole supports you to build up European projects.
Contact : Emilie Romeo, Europe Project Manager - emilie.romeo@lyonbiopole.com        

Learn more


03/2015 - H2020 SME Instrument

H2020 program includes the SME instrument. It targets the highly innovative SMEs with a strong ambition to develop, grow and internationalize;  focusing on the delivery of new products, services or processes on the market. For SMEs in the health sector, the SME instrument is focused on the PHC-12 Clinical research for the validation of biomarkers and / or diagnostic medical devices line. The project can be presented by a single SME, and different phases depending on the maturity of the project. Next submission deadline: Phase 1 & 2 projects = 06/17/2015. Lyonbiopole supports you to build up European projects.
Contact : Emilie Romeo, Europe Project Manager - emilie.romeo@lyonbiopole.com        
 

03/09-04/28/2015 - Sanofi - Institut Pasteur Awards 2015

These Awards will honor four scientists, whose outstanding research in the life sciences is contributing to progress in global health, specifically in the following fields: Tropical and neglected diseases, Neurodenegerative deseases and ageing, Drug resistance and Immunology. The deadline to submit nominations is Tuesday, 28th April, 2015.

Learn more


03-23/04-24/2015 - Discovery Fast Track Challenge

Do you have a drug discovery concept? Are you a principal investigator affiliated with a European¹ research institute, college or university? Are you excited about partnering with a leading pharmaceutical company to translate your novel science into a new medicine? If so, the Discovery Fast Track Challenge is for you.

Learn more



A LA UNE
03/20/2015 - Your future parnerships are waiting for you !

Lyonbiopole facilitates links between Rhône-Alpes health actors through its online community of nearly 270 profiles (companies, investors, healthcare institutions, research units). This year, a new segmentation has been attributed to companies. The aim is to follow the expansion of the cluster to include new themes. Find alos the online profiles of 182 collaborative R&D projects accredited by Lyonbiopole, presented in a brand new design. Finally, the 1st edition of the Clinical Research Structures Directory is online. Your future partnerships are waiting for you, visit lyonbiopole.com.
Contact : Claudia Bargeon, Communication Assistant - claudia.bargeon@lyonbiopole.com

Learn more


03/19/2015 - Systems Medicine Web Hub

As part of the EC coordination action CASyM the idea of a Systems Medicine Web Hub has been developed. The hub provides scientists, projects and other relevant initiatives with an opportunity to share information related to events, research outcomes, positions etc. A central hub will increase the visibility and impact of your work.

Learn more


03/09-11/2015 - Lyonbiopole present at BioEurope Spring

Lyonbiopole welcomed 32 of its Rhône-Alpes members on the joint stand of the French health competitiveness clusters, in Paris. Participants received significant visibility with 2400 participants present from 51 countries. More than 12 439 business meetings have also given rise to future collaborations.

Learn more


03/27/2015 - Flamel Technologie announces positive results

Flamel Technologies announced the results of a First-in-Man (FIM) clinical study in healthy volunteers using its proprietary LiquiTime® drug delivery platform applied to guaifenesin, a broadly used expectorant. LiquiTime is designed to provide a controlled, extended release of oral liquids principally for pediatric and geriatric patients. 

Learn more


03/20/2015 - iDD biotech enters worldwide agreement with Genmab

iDD biotech has announced the signing of an agreement with Genmab, a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Under the terms of the agreement, Genmab will pay at iDD Biotech an upfront fee of EUR 2.5 million. Future payments range from a minimum of EUR 3.5 million to potentially EUR 101.5 million in development and sales milestones and single-digit royalties on commercialized products.

Learn more


03/18/2015 - EU Lead Factory awards Cellipse

Cellipse was awarded an exclusive High Throughput Screening research program to screen the EU Lead Factory’s (ELF) joint compound library on an undisclosed innovative therapeutic target by the Selection Committee on January 19 2015. 

Learn more


03/17/2015 - Valneva announces signing licence agreement with China

Valneva announces signing of an exclusive license agreement on EB66® Cell Line for Human and Veterinary Vaccines in People’s Republic of China

Learn more


03/12/2015 - Valneva : 2 new deals

Valneva, a leading pure play vaccines biotech company, announced today that it has signed a new research license agreement with Merial and a commercial license agreement with an undisclosed European company to develop veterinary vaccines using Valneva’s EB66® vaccine cell line platform.

Learn more


03/02/2015 - Alizé Pharma lauches Phase II clinical trial

Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.

Learn more


03/02/2015 - Synthelis and Horiba

They present a series of experiments realized with functional CxCR4-containing proteoliposomes produced by SYNTHELIS, using a patented cell-free system, to study the interaction with clinically relevant ligands, such as SDF1-#, T22 and AMD 3100. We demonstrate the interest of the SPRi technology (HORIBA Scienti!c) for the determination of GPCR-ligand interactions, independently of the binding site. These results confirm the usefulness of SPRi as a technique to carry out primary screenings and to obtain relevant pharmacokinetic data.

Learn more

 
© Lyonbiopole 2019  |  CREDITS  |  LEGAL NOTICE  |